ANI Pharmaceuticals Inc (ANIP)
Working capital turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 614,376 | 486,816 | 316,385 | 216,136 | 208,475 |
Total current assets | US$ in thousands | 527,684 | 519,816 | 344,261 | 321,775 | 170,321 |
Total current liabilities | US$ in thousands | 193,680 | 145,477 | 99,439 | 87,537 | 78,565 |
Working capital turnover | 1.84 | 1.30 | 1.29 | 0.92 | 2.27 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $614,376K ÷ ($527,684K – $193,680K)
= 1.84
The working capital turnover of ANI Pharmaceuticals Inc has fluctuated over the five-year period from 2020 to 2024. In 2020, the company had a working capital turnover of 2.27, indicating that it turned its working capital 2.27 times during that year. However, this ratio decreased significantly in 2021 to 0.92, suggesting a slower rate of working capital utilization.
Subsequently, there was a slight improvement in 2022 with a working capital turnover of 1.29, followed by a similar performance in 2023, where the ratio was 1.30. The most notable increase was seen in 2024, with a working capital turnover of 1.84, indicating that the company efficiently utilized its working capital to generate revenue.
Overall, while there have been fluctuations in ANI Pharmaceuticals Inc's working capital turnover over the years, the company managed to increase this ratio by the end of the period, potentially indicating better management of its working capital resources. However, further analysis of the company's operating and financial strategies may be necessary to understand the reasons behind these fluctuations.
Peer comparison
Dec 31, 2024